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Abstract
Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is an ether phospholipid
mediator associated with platelet coagulation, but also subserves inflammatory roles. The PAF receptor
(provisional nomenclature recommended by NC-IUPHAR [37]) is activated by PAF and other suggested
endogenous ligands are oxidized phosphatidylcholine [73] and lysophosphatidylcholine [96]. It may also be
activated by bacterial lipopolysaccharide [89].
Contents
This is a citation summary for Platelet-activating factor receptor in the Guide to Pharmacology database
(GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the
database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database
which are given here under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
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